Prosecution Insights
Last updated: April 19, 2026

Examiner: NIEBAUER, RONALD T

Tech Center 1600 • Art Units: 1654 1658 1676

This examiner grants 41% of resolved cases

Performance Statistics

41.3%
Allow Rate
-18.7% vs TC avg
788
Total Applications
+33.3%
Interview Lift
1286
Avg Prosecution Days
Based on 712 resolved cases, 2023–2026

Rejection Statute Breakdown

6.8%
§101 Eligibility
19.2%
§102 Novelty
28.2%
§103 Obviousness
28.1%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18035267 PEPTIDES FROM HUMAN B-CASEIN THAT HAVE ANTI-BACTERIAL ACTIVITY Non-Final OA The Regents of the University of California
18303796 SOLUBLE THY-1 COMPOSITIONS AND USE THEREOF TO TREAT OR REVERSE FIBROSIS Non-Final OA The Regents of the University of California
18250406 PEPTIDE TAG AND TAGGED PROTEIN CONTAINING SAME Non-Final OA IDEMITSU KOSAN CO.,LTD.
18004104 HUMAN RECOMBINANT ACE2-FC MUTANTS THAT DECOUPLE ANTI-SARS-COV-2 ACTIVITY FROM CARDIOVASCULAR EFFECTS Non-Final OA Northwestern University
17288879 SYNTHETIC PEPTIDES INDUCING IMMUNOGENIC CELL DEATH Final Rejection CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
18041289 PEPTIDES AND FORMULATIONS FOR CANCER TREATMENT Non-Final OA Peptinovo Biopharma, Inc.
18449907 IODINATED CROSSLINKED HYDROGELS AND METHODS OF FORMING THE SAME Non-Final OA Boston Scientific Scimed, Inc.
18492014 INSECT NEUROPEPTIDES 7 Non-Final OA Solasta Bio Limited
18246063 POLYMERS AND NANOPARTICLE FORMULATIONS FOR SYSTEMIC NUCLEIC ACID DELIVERY Non-Final OA The Johns Hopkins University
17628142 SEPARATED PEPTIDE Non-Final OA National University Corporation Tokai National Higher Education and Research System
17418305 METHOD FOR STABILIZING BIOACTIVITY OF GROWTH FACTOR Final Rejection National Cheng Kung University
18717568 PEPTIDES AND COMPOSITIONS FOR USE IN COSMETICS Final Rejection LIPOTRUE, S.L.
18248240 NOVEL PEPTOIDS AND USE THEREOF FOR PREVENTING OR TREATING CHRONIC PAIN Non-Final OA Université de Montpellier
18002478 LONG ACTING GLP-1/GIP DUAL AGONISTS Non-Final OA SUN PHARMACEUTICAL INDUSTRIES LIMITED
18620789 METHODS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION Final Rejection Stealth BioTherapeutics Inc.
18460346 METHODS AND COMPOSITIONS FOR TREATING, PREVENTING, INHIBITING, AMELIORATING OR DELAYING THE ONSET OF OPHTHALMIC CONDITIONS Non-Final OA Stealth BioTherapeutics Inc.
18131280 PEPTIDIC OLIGOMERS AND METHODS OF USING THE SAME Non-Final OA THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
18037287 PROTEIN HYDROGELS AND METHODS FOR THEIR PREPARATION Non-Final OA THE UNIVERSITY OF BRITISH COLUMBIA
17935255 METHODS FOR TREATING LIVER DISEASE Non-Final OA SORBONNE UNIVERSITÉ
17928759 EFFICIENT PEPTIDE CONDENSATION METHOD FOR DIFFICULT SEQUENCES Non-Final OA Chugai Seiyaku Kabushiki Kaisha
18534263 MATRIPTASE AND U-PLASMINOGEN ACTIVATOR SUBSTRATES AND OTHER CLEAVABLE MOIETIES AND METHODS OF USE THEREOF Final Rejection CytomX Therapeutics, Inc.
18097077 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES Final Rejection Protagonist Therapeutics, Inc.
16104037 Composition and Method for Therapeutic Agent Delivery During Pregnancy Non-Final OA University of Mississippi Medical Center
15694592 MOLECULAR SENSORS Final Rejection UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
17629313 PEPTIDE HAVING HAIR GROWTH PROMOTING ACTIVITY, AND USE THEREOF Final Rejection CAREGEN CO., LTD.
18041729 ANNEXIN A1 N-TERMINAL PEPTIDE FORMULATIONS AND METHODS Non-Final OA ResoTher Pharma A/S
17455880 NERVE GROWTH FACTOR MUTANT Final Rejection Staidson (Beijing) Biopharmaceuticals Co., Ltd.
17996875 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER Final Rejection L-BASE CO., LTD.
17918930 NOVEL ALPHA-HELICAL DOUBLE-SIDED CELL PENETRATING PEPTIDE AND USE THEREOF Final Rejection CAMP THERAPEUTICS INC.
17995092 NOVEL ANTIBACTERIAL PEPTIDE AND USE THEREOF Final Rejection ANYGEN CO., LTD.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month